Søsterhjemmet, Kirkeveien 166, 2.etasje (map)
Victimization was associated with symptoms of poor mental health, more serious substance use and unstable housing.
In the 12-week, open-label, randomized-controlled study, 159 patients with opioid dependence were randomized to treatment with either extended-release naltrexone or buprenorphine-naloxone, following detoxification.
A new article from the NorComt study at SERAF examine how patients are doing one year after starting in treatment and investigate the impact of abstinent networks.
In a systematic review of all quality of life questionnaires used among opioid users in the last 25 years, researchers found out that the questionnaires were rarely adapted to this particular group.
Overdose death is the most common cause of death after release from prison among Norwegian prisoners. The increased risk of overdose death starts immediately after release.
As part of large randomized control trial of exercise within alcohol treatment in Denmark, SERAF contributed to a qualitative analysis of the reasons why some participants dropped out.
As part of the National Overdose Strategy, researchers at SERAF have developed and implemented a multi-site naloxone distribution program. There were over 2,000 naloxone nasal sprays distributed in the project’s first year and a half, with the majority of those reaching people known to be at risk of overdosing.
In collaboration with Bergen Ambulance Services, researchers at SERAF analyzed patient data for 463 overdoses from 2012 to 2013. Cases were included if the victim responded to naloxone, the opioid overdose antidote, indicating an opioid overdose.